Coca-Cola HBC AG

Coca-Cola HBC is one of Coca-Cola’s largest strategic bottlers, producing, distributing and marketing drinks in 29 countries to around 740 million consumers. Alongside Coca-Cola, Fanta and Sprite, it handles water, coffee, energy and sports drinks, and even premium alcoholic beverages, making the business considerably more diverse than its name initially suggests.

CCH combines high-quality insider buying with strong fundamentals, better-than-expected growth, reasonable valuation and a healthy long-term technical structure. CEO Zoran Bogdanovic bought 4,750 shares at £42.69 and COO Panagiota Kalogeraki bought 3,600 at £42.715358, almost simultaneously after a material correction. Combined purchases were approximately £356,600.

The reference price of 4,408p = £44.08 is only about 3.2–3.3% above their purchase prices. The monthly chart remains constructive; the daily chart still needs confirmation but does not invalidate the thesis. Complete assessment on 22 September 2026: 9.1/10 — 9+ SIGNAL.

Initial signal window: 14 days, from 22/09/2026 to 06/10/2026.

Reported facts: CEO Zoran Bogdanovic: 4,750 shares at £42.69, approximately £202,778. COO Panagiota Kalogeraki: 3,600 shares at £42.715358, approximately £153,775. Combined total: approximately £356,600. The voluntary purchases occurred on the same day after a significant correction. The exact transaction date was not specified in the supplied summary.

INSIDER9+ interpretation: Near-simultaneous CEO and COO purchases form a high-quality senior-management cluster close to an important technical zone. Rating: 9.4/10. Absolute financial materiality is below exceptional purchases worth tens of millions, so the rating is not 10/10. This does not guarantee appreciation.

Rating: 9.6/10. The reference price of 4,408p equals £44.08, not £4,408. It is approximately 3.2–3.3% above the CEO’s £42.69 and the COO’s £42.715358 purchase prices.

There has been no material rally since the purchases. The insiders bought after the sell-off and the price remains close to that region. The daily reaction around £42.0–42.8 supports the timing assessment without constituting a buy instruction.

Rating: 9.4/10. First-half 2026: reported revenue +10.8%, organic revenue +9.6%, comparable EBIT +17.0%, organic EBIT +15.2%, net profit +11.4% and comparable EPS +15.2%.

The assessment is of a profitable, operationally mature company with quality growth. It does not depend on an accounting turnaround to demonstrate profitability.

Rating: 9.2/10. Organic revenue growth close to 10%, EBIT growth around 15%, EPS growth and operational expansion are strong results for a company of this scale and maturity.

Management raised 2026 guidance: organic revenue growth at the top of the 6–7% range and organic EBIT growth of 8–10%. The assessment considers this high-quality growth for a mature company.

Rating: 8.8/10. P/E in the high teens, forward P/E in the mid-teens and PEG approximately 1.3.

These multiples are compatible with growth, margins, business quality and operational stability. Valuation is reasonable, with no obvious overvaluation, but is not exceptionally cheap and should not be presented as deep value or a bargain.

Rating: 8.3/10. Recent sales by other PDMRs justify a moderate penalty.

Automatic Employee Share Purchase Plan transactions must not be confused with discretionary purchases. The current purchases are different: the CEO and COO voluntarily bought in the market almost simultaneously. This materially strengthens the current signal.

Rating: 9.1/10.

1. Organic growth: performance ahead of initial expectations.

2. Margins and guidance: margin expansion and raised management guidance.

3. CCBA: agreement to acquire 75% of Coca-Cola Beverages Africa for approximately $2.6 billion, adding 14 African markets. The combination is expected to create the world’s second-largest Coca-Cola bottler by volume. Completion is expected by the end of 2026, subject to required approvals.

Rating: 7.9/10. 10 means lower risk. The CCBA acquisition is both a catalyst and a risk.

1. Integration and execution: African expansion, operational execution and arrangements relating to the remaining 25%.

2. Financing: debt use and share issuance associated with the transaction.

3. Geographic and currency exposure: macroeconomic, currency and increased African-market risks.

In 2025, net debt/EBITDA was approximately 0.7x and free cash flow around €700 million. Financial capacity exists, but the acquisition is not risk-free.

Rating: 8.2/10. At 4,408p (£44.08), the shares sit almost on the chart’s long moving average near 4,406p, but below the other two averages around 4,551p and 4,699p. Short- and medium-term conditions are not fully repaired. Daily RSI around 43 is weak/moderate without extreme deterioration.

The latest candle is constructive: opening near 4,284p, low at 4,280p, then recovery to 4,408p, approximately +3%. This suggests demand near the insider purchase area but does not fully confirm a daily reversal. Recovering 4,550–4,700p would materially improve the chart.

Rating: 9.3/10. Monthly reading: the structure is not broken. At 4,408p, the shares remain above the visible monthly averages around 3,049p and 2,381p, both rising. Monthly RSI near 60 indicates positive momentum without obvious extreme overbought conditions.

Since 2022, higher highs and higher lows remain in place. The shares rose from approximately 1,500p to above 5,000p before the current correction. The reading is of a correction within a larger trend that remains healthy.

Support near 4,102p broadly coincides with a former breakout area. The £41–42 zone is structurally important: support, the former breakout and insider purchases converge around it.

4,100p = £41.00: main support. 4,400p = £44.00: long average / current zone. 4,550p = £45.50: first important recovery. 4,700p = £47.00: stronger confirmation. 4,890p = £48.90: relevant resistance. 5,200p = £52.00: recent highs.

Recovering 4,550–4,700p would strengthen the daily chart. A clear loss of 4,102p would weaken structural support. These are research monitoring levels, not buy or sell orders.

CCH · London Stock Exchange · quoted in GBX (pence); this research displays prices in GBP. EEE · Euronext Athens · EUR. Ordinary shares in the same company, ISIN CH0198251305.

CCH combines high-quality factors: CEO and COO bought together after a correction, the price remains around 3% above their purchases, fundamentals are strong, management raised guidance, valuation is reasonable and the monthly structure remains healthy.

The daily chart needs confirmation: it remains below the short- and medium-term averages; recovery above 4,550p and then 4,700p would strengthen the assessment. CCBA adds growth potential alongside financial and execution risks.

SIGNAL SCORE: 9.1/10 — 9+ SIGNAL — 22/09/2026. The final rating is weighted, not a simple arithmetic average of the axes. No later assessment exists yet.

Research intended for a general audience. It does not constitute personalised investment advice. Investing involves risk of capital loss.

Positive factors: recovery above 4,550p and then 4,700p; holding £41–42 support; operations exceeding guidance; positive progress in the CCBA acquisition and integration.

Negative factors: a clear loss of 4,102p; deteriorating fundamentals; excessive CCBA risk; a significant balance-sheet change or new material events. Every complete reassessment creates a new snapshot while preserving the original signal score.